Reversal of tumor induced dendritic cell paralysis: A treatment regimen against cancer

Current Immunology Reviews

Volumn 2, Issue 3, 2006, Pages 261-272

  Murugaiyan, Gopal ^a   Basak, Saroj ^b   Saha, Bhaskar ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dendritic cells; Interleukin 10; Prostanoids; Transforming growth factor ; Tumor immune evasion; Vascular endothelial growth factor

Indexed keywords

CANCER VACCINE; CYCLOOXYGENASE 2; DENDRITIC CELL VACCINE; DRUG ANTIBODY; GAMMA INTERFERON; GANGLIOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 6; PROSTAGLANDIN E2; PROSTANOID; RECOMBINANT VASCULOTROPIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL INFILTRATION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; GENE THERAPY; HEAD AND NECK CANCER; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INNATE IMMUNITY; LIVER CELL CARCINOMA; MELANOMA; MYELOMA; NATURAL KILLER CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; T CELL LYMPHOMA; T LYMPHOCYTE; TUMOR GROWTH; TUMOR REGRESSION;

EID: 33747213988     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339506778018523     Document Type: Review

References (164)

1. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003; 21: 807-39.
2. Smyth MJ, Godfrey DI, Trapani JA, A fresh look at tumor immunosurveillance and immunotherapy Nat Immunol 2001; 2: 293-9.
3. Naftzger C, Houghton AN. Tumor immunology. Nat Immunol 2001; 2: 293-9.
4. Ohtani H. Stromal reaction in cancer tissue: patho-physiologic significance of the expression of matrix-degrading enzymes in relation to matrix turnover and immune/inflammatory reactions. Pathol Int 1998; 48: 1-9.
5. Dano K, Romer J, Nielsen BS, et al. Cancer invasion and tissue remodeling-cooperation of protease systems and cell types. APMIS 1999; 107: 120-7.
6. Raulet DH. Interplay of natural killer cells and their receptors with the adaptive immune response. Nat Immunol 2004; 5: 996-1002.
7. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Inummol 2003; 3: 781-90.
8. Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res 2003; 90:127-56.
9. Fernandez NC, Lozier A, Flament C, et al. DC directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999; 5: 405-11.
10. Nishioka Y, Nishimura N, Suzuki Y, Sone S. Human monocyte-derived and CD83(+) blood DC enhance NK cell-mediated cytotoxicity. Eur J Immumol 2001; 31: 2633-41.
11. Borg C, Jalil A, Laderach D, et al. NK cell activation by DC(DC) requires the formation of a synapse leading to IL-12 polarization in DC. Blood 2004; 104: 3267-75.
12. Yu Y, Hagihara M, Ando K, et al. Enhancement of human cord blood CD34+ cell-derived NK cell cytotoxicity by dendritic cells. J Immunol 2001; 166: 1590-600.
13. Semino C, Angelini G, Poggi A, Rubartelli A. NK/iDC interaction results in IL-18 secretion by DC at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood 2005; 106: 609-16.
14. Granucci F, Zanoni I, Pavelka N, et al. A contribution of mouse dendritic cell-derived IL-2 for NK cell activation. J Exp Med 2004; 200: 287-95.
15. Osada T, Nagawa H, Kitayama J, et al. Peripheral blood dendritic cells, but not monocyte-derived dendritic cells, can augment human NK cell function. Cell Immunol 2001; 213: 14-23.
16. Wilson JL, Heffler LC, Charo J, Scheynius A, Bejarano MT, Ljunggren HG. Targeting of human DC by autologous NK cells. J Immunol 1999; 163: 6365-70.
17. Chambers BJ, Salcedo M, Ljunggren HG. Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity 1996; 5: 311-7.
18. Geldhof AB, Moser M, De Baetselier P. IL-12-activated NK cells recognize B7 costimulatory molecules on tumor cells and autologous dendritic cells. Adv Exp Med Biol 1998; 451: 203-10.
19. Turner JG, Rakhmilevich AL, Burdelya L, Neal Z, Imboden M, Sondel PM, Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells. Yu H. J Immunol 2001; 166: 89-94.
20. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002; 195: 327-33.
21. Vitale M, Della Chiesa M, Carlomagno S, et al. NK-dependent DC maturation is mediated by TNF-alpha and IFN-gamma released upon engagement of the NKp30 triggering receptor. Blood 2005; 106: 566-71.
22. Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of DC by natural killer cells. J Exp Med 2002; 195: 335-41.
23. Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 2001; 13: 459-63.
24. Smyth MJ, Thia KY, Street SE, et al. Differential tumor surveilance by natural killer (NK) and NKT cells. J Exp Med 2000; 191: 661-8.
25. Shibolet O, Alper R, Zlotogarov L, et al. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells. Int J Cancer 2003; 106: 236-43.
26. Kitamura H, Iwakabe K, Yahata T, et al. The natural killer T (NKT) cell ligand alpha-galactosyl ceramide demonstrates its immuno-potentiating effect by inducing interleukin (IL)-12 production by DC and IL-12 receptor expression on NKT cells. J Exp Med 1999; 189: 1121-8.
27. Nishimura T, Kitamura H, Iwakabe K, et al. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing DC to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int Immurol 2000; 12: 987-94.
28. Adam C, King S, Allgeier T, et al. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. Blood 2005; 106: 338-44.
29. Hermans IF, Silk JD, Gileadi U, et al. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 2003; 171: 5140-7.
30. Verhasselt V, Buelens C, Willems F, De Groote D, Haeffner-Cavaillon N, Goldman M. Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendritic cells: evidence for a soluble CD14-dependent pathway. J Immunol 1997; 158: 2919-25.
31. Lu L, Qian S, Hershberger PA, Rudert WA, Lynch DH, Thomson AW. Fas ligand (CD95L) and B7 expression on DC provide counter-regulatory signals for T cell survival and proliferation. J Immunol 1997; 158: 5676-84.
32. Lu L, Bonham CA, Chambers FG, et al. Induction of nitric oxide synthase in mouse DC by IFN-gamma, endotoxin, and interaction with allogeneic T cells: nitric oxide production is associated with dendritic cell apoptosis. J Immunol 1996; 157: 3577-86.
33. Bonham CA, Lu L, Li Y, Hoffman RA, Simmons RL, Thomson AW. Nitric oxide production by mouse bone marrow-derived dendritic cells: implications for the regulation of allogeneic T cell responses. Transplantation 1996; 62: 1871-7.
34. Thurnher M, Radmayr C, Ramoner R, et al. Human renal-cell carcinoma tissue contains dendritic cells. Int J Cancer 1996; 68: 1-7.
35. Chaux P, Favre N, Martin M, Martin F. Tumor-infiltrating DCare defective in their antigen-presenting function and inducible B7 expression in rats. Int J Cancer 1997; 72: 619-24.
36. Zeid NA, Muller HK. S100 positive DCin human lung tumors associated with cell differentiation and enhanced survival. Pathology 1993; 25: 338-43.
37. Becker Y. Anticancer role of DC(DC) in human and experimental cancers-a review. Anticancer Res 1992; 12: 511-20.
38. Yang S, Darrow TL, Vervaert CE, Seigler HF. Immunotherapeutic potential of tumor antigen-pulsed and unpulsed DC generated from murine bone marrow. Cell Immunol 1997; 179: 84-95.
39. Candido, KA, Shimizu K, McLaughlin JC, et al. Local administration of DCinhibits established breast tumor growth: implications for apoptosis-inducing agents. Cancer Res 2001; 61: 228-36.
40. Specht JM, Wang G, Do MT, et al. DC retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 1997; 186: 1213-21.
41. Chapoval AI, Tamada K, Chen L. In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells. Blood 2000; 95: 2346-51.
42. Manna PP, Mohanakumar T. Human dendritic cell mediated cytotoxicity against breast carcinoma cells in vitro. J Leukoc Biol 2002; 72: 312-20.
43. Vanderheyde N, Vandenabeele P, Goldman M, Willems F. Distinct mechanisms are involved in tumoristatic and tumoricidal activities of monocyte-derived dendritic cells. Immunol Lett 2004; 91: 99-101.
44. Joo HG, Fleming TP, Tanaka Y, et al. Human DC induce tumor-specific apoptosis by soluble factors. Int J Cancer 2002; 102: 20-8.
45. Lu G, Janjic BM, Janjic J, Whiteside TL, Storkus WJ, Vujanovic NL. Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand, J Immunol 2002; 168: 1831-9.
46. Shi J, Ikeda K, Fujii N, et al. Activated human umbilical cord blood DC kill tumor cells without damaging normal hematological progenitor cells. Cancer Sci 2005; 96: 127-33.
47. Yang R, Xu D, Zhang A, Gruber A. Immature DC kill ovarian carcinoma cells by a FAS/FASL pathway, enabling them to sensitize tumor-specific CTLs. Int J Cancer 2001; 94: 407-13.
48. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767-811.
49. Wykes M, Pombo A, Jenkins C, McPherson GG. DC interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. J Immunol 1998; 161: 1313-9.
50. Dubois B, Massacrier C, Vanbervliet B, et al. Critical role of IL-12 in dendritic cell-induced differentiation of naive B lymphocytes. J Immunol 1998; 161: 2223-31.
51. Wu J, Qin D, Burton GF, Szakal AK, Tew JG. Follicular dendritic cell-derived antigen and accessory activity in initiation of memory IgG responses in vitro. J Immunol 1996; 157: 3404-11.
52. Dubois B, Vanbervliet B, Fayette J, et al. DC enhance growth and differentiation of CD40-activated B lymphocytes. J Exp Med 1997; 185: 941-51.
53. MacPherson G, Kushnir N, Wykes M. Dendritic cells, B cells and the regulation of antibody synthesis. Immunol Rev 1999; 172: 325-34.
54. Fayette J, Dubois B, Vandenabeele S, et al. Human DC skew isotype switching of CD40-activated naive B cells towards IgA1 and IgA2, J Exp Med 1997; 185: 1909-18.
55. Wykes M, MacPherson G. Dendritic cell-B-cell interaction: DC provide B cells with CD40-independent proliferation signals and CD40-dependent survival signals. Immunology 2000; 100: 1-3.
56. Ochsenbein AF. Immunological ignorance of solid tumors. Springer Semin Immunopathol 2005; 27: 19-35.
57. Oppenheim DE, Roberts SJ, Clarke SL, et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 2005; 6: 928-37.
58. Wiemann K, Mittrucker HW, Feger U, et al. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J Immunol 2005; 175: 720-9.
59. Cabrera T, Lopez-Nevot MA, Gaforio JJ, Ruiz-Cabello F, Garrido F. Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother 2003; 52: 1-9.
60. Campoli M, Chang CC, Ferrone S. HLA class I antigen loss, tumor immune escape and immune selection. Vaccine 2002; 20: 40-5.
61. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005; 10: 86-103.
62. Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, Vile RG. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 1998; 4: 581-7.
63. Multhoff G. Activation of natural killer cells by heat shock protein 70. Int J Hyperthermia 2002; 18: 576-85.
64. Beckman RA, Loeb LA. Genetic instability in cancer: theory and experiment. Semin Cancer Biol 2005; 15: 423-35.
65. Chen Q, Daniel V, Maher DW, Hersey P. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 56: 755-60.
66. Tada T, Ohzeki S, Utsumi K, et al. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol 1991; 146: 1077-82.
67. Inge TH, Hoover SK, Susskind BM, Barrett SK, Bear HD. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1. Cancer Res 1992; 52: 1386-92.
68. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat Med 1996; 2: 1361-6.
69. Shurin GV, Gerein V, Lotze MT, Barksdale EM Jr. Apoptosis induced in T cells by human neuroblastoma cells: role of Fas ligand. Nat Immun 1998; 16: 263-74.
70. Gastman BR, Atarshi Y, Reichert TE, et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 1999; 59: 5356-64.
71. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793-800.
72. Muta K, Olishima K, Abe Y, et al. Expression of human tumor-associated antigen RCAS1 in adult T-cell leukemia/lymphoma. Int J Hematol 2004; 79: 340-4.
73. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9: 1269-74.
74. Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by tryptophan catabolism, Cell Death Differ 2002; 9: 1069-77.
75. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-9.
76. Antony PA, Piccirillo CA, Akpinarli A, et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005; 174: 2591-601.
77. Smyth MJ, Teng MW, Swann J, Kyparissoudis K, Godfrey DI, Hayakawa Y. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 2006; 176: 1582-7.
78. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69: 4-10.
79. Plate KH, Breier G, Weich HA, Mennel HD, Risau W. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 1994; 59: 520-9.
80. Landriscina M, Cassano A, Ratto C, et al. Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br J Cancer 1998; 78: 765-70.
81. Fontanini G, Boldrini L, Calcinai A, et al. Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density. Clin Cancer Res 1999; 5: 155-61.
82. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55: 3964-8.
83. Ohta Y, Endo Y, Tanaka M, et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res 1996; 2: 1411-6.
84. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001; 19: 577-83.
85. Hyodo I, Doi T, Endo H, et al. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 1998; 34: 2041-5.
86. Rudlowski C, Pickart AK, Fuhljahn C, et al. Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int J Gynecol Cancer 2006; 16: 183-9.
87. Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Inummol Res 2001; 23: 263-72.
88. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999; 5: 2963-70.
89. Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of DC and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92: 4150-66.
90. Ohm JE, Shurin MR, Esche C, Lotze MT, Carbone DP, Gabrilovich DI. Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J Immunol 1999; 163: 3260-8.
91. Strauss L, Volland D, Kunkel M, Reichert TE. Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogenesis and immune tolerance. Med Sci Monit 2005; 11: 280-92.
92. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096-103.
93. Dikov MM, Ohm JE, Ray N, et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol 2005; 174: 215-22.
94. Oyama T, Ran S, Ishida T, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998; 160: 1224-32.
95. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333: 328-35.
96. Roberts AB. Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 2003; 100: 8621-3.
97. Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev 1996; 7: 93-102.
98. Gold LI. The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit Rev Oncog 1999; 10: 303-60.
99. Wakefield LM, Roberts AB. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002; 12: 22-9.
100. de Visser KE, Kast WM. Effects of TGF-beta on the immune system: implications for cancer immunotherapy. Leukemia 1999; 13: 1188-99.
101. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming Growth Factor-beta Regulation of Immune Responses. Annu Rev Immunol 2006; 24: 99-146.
102. Kehrl JH, Taylor A, Kim SJ, Fauci AS. Transforming growth factor-beta is a potent negative regulator of human lymphocytes. Ann N Y Acad Sci 1991; 628: 345-53.
103. Torre-Amione G, Beauchamp RD, Koeppen H, et al. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 1990; 87: 1486-90.
104. Tsushima H, Kawata S, Tamura S, et al. High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology 1996; 110: 375-82.
105. Inge TH, Hoover SK, Susskind BM, Barrett SK, Bear HD. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1. Cancer Res 1992; 52: 1386-92.
106. Rook AH, Kehrl JH, Wakefield LM, et al. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 1986; 136: 3916-20.
107. Friese MA, Wischhusen J, Wick W, et al. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 2004; 64: 7596-603.
108. Strobl H, Knapp W. TGF-beta1 regulation of dendritic cells. Microbes Infect 1999; 1: 1283-90.
109. Kao JY, Gong Y, Chen CM, Zheng QD, Chen JJ. Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine. J Immunol 2003; 170: 3806-11.
110. Kobie JJ, Wu RS, Kurt RA, et al. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 2003; 63: 1860-4.
111. Weber F, Byrne SN, Le S, et al. Transforming growth factor-beta1 immobilizes DC within skin tumors and facilitates tumour escape from the immune system. Cancer Immunol Immunother 2005; 54: 898-906.
112. Huang A, Gilmour JW, Imami N, Amjadi P, Henderson DC, Allen-Mersh TG. Increased serum transforming growth factor-beta1 in human colorectal cancer correlates with reduced circulating DC and increased colonic Langerhans cell infiltration. Clin Exp Immunol 2003; 134: 270-8.
113. Buelens C, Verhasselt V, De Groote D, Thielemans K, Goldman M, Willems F. Interleukin-10 prevents the generation of DC from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/ macrophage-colony-stimulating factor. Eur J Immunol 1997; 27: 756-62.
114. Allavena P, Piemonti L, Longoni D, et al. IL-10 prevents the differentiation of monocytes to DC but promotes their maturation to macrophages. Eur J Immunol 1998; 28: 359-69.
115. Kalinski P, Schuitemaker JH, Hilkens CM, Kapsenberg ML. Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendrific cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J Immumol 1998; 161: 2804-9.
116. Fortsch D, Rollinghoff M, Stenger S. IL-10 converts human DC into macrophage-like cells with increased antibacterial activity against virulent Mycobacterium tuberculosis. J Immunol 2000; 165: 978-87.
117. Beckebaum S, Zhang X, Chen X, et al. Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin Cancer Res 2004; 10: 7260-9.
118. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell functions in humans after injection of immature dendritic cells. J Exp Med 2001; 193: 233-8.
119. Dhodapkar MV, Krasovsky J, Steinman RM, Bhardwaj N. Mature DC boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. J Clin Invest 2000; 105: 9-14.
120. Reichardt VL, Brossart P. DC in clinical trials for multiple myeloma. Methods Mol Med. 2005; 109: 127-36.
121. Gerlini G, Tun-Kyi A, Dudli C, Burg G, Pimpinelli N, Nestle FO. Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on DC in metastatic tumor lesions. Am J Pathol 2004; 165: 1853-63.
122. Shurin MR, Yurkovetsky ZR, Tourkova IL, Balkir L, Shurin GV. Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10. Int J Cancer 2002; 101: 61-8.
123. Chi-Man Tang T, Tung-Ping Poon R, Fan ST. The significance of cyclooxygenase-2 expression in human hepatocellular carcinoma. Biomed Pharmacother 2005; 59: 311-6.
124. Verburg KM, Maziasz TJ, Weiner E, Loose L, Geis GS, Isakson PC. Cox-2-specific inhibitors: definition of a new therapeutic concept. Am J Ther 2001; 8: 49-64.
125. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 2000; 19: 19-27.
126. Simmons DL, Butting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004; 56: 387-437.
127. Dannenberg AJ, Zakim D. Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2. Semin Oncol 1999; 26: 499-504.
128. Sharma S, Yang SC, Zhu L, et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res 2005; 65: 5211-20.
129. Sharma S, Zhu L, Yang SC, et al. Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses. J Immunol 2005; 175: 813-9.
130. Sombroek CC, Stam AG, Masterson AJ, et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol 2002; 168: 4333-43.
131. Pockaj BA, Basu GD, Pathangey LB, et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol 2004; 11: 328-39.
132. Sharma S, Stolina M, Yang SC, et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 2003; 9: 961-8.
133. Harizi H, Juzan M, Pitard V, Moreau JF, Gualde N. Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J Immunol 2002; 168: 2255-63.
134. Whittaker DS, Bahjat KS, Moldawer LL, Clare-Satzler MJ. Autoregulation of human monocyte-derived dendritic cell maturation and IL-12 production by cyclooxygenase-2-mediated prostanoid production. J Immunol 2000; 165: 4298-304.
135. Harizi H, Grosset C, Gualde N. Prostaglandin E2 modulates dendritic cell function via EP2 and EP4 receptor subtypes. J Leukoc Biol 2003; 73: 756-63.
136. Yang L, Yamagata N, Yadav R, et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest 2003; 111: 727-35.
137. Akasaki Y, Liu G, Chung NH, Ehtesham M, Black KL, Yu JS. Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol 2004; 173: 4352-9.
138. Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000; 164: 361-70.
139. McKallip R, Li R, Ladisch S. Tumor gangliosides inhibit the tumor-specific immune response. J Immunol 1999; 163: 3718-26.
140. Alessandri G, Filippeschi S, Sinibaldi P, et al. Influence of gangliosides on primary and metastatic neoplastic growth in human and murine cells. Cancer Res 1987; 47: 4243-4247.
141. Sung CC, Pearl DK, Coons SW, Scheithauer BW, Johnson PC, Yates AJ. Gangliosides as diagnostic markers of human astrocytomas and primitive neuroectodermal tumors. Cancer 1994; 74: 3010-3022.
142. Ladisch S, Wu ZL, Feig S, et al. Shedding of GD2 ganglioside by human neuroblastoma. Int J Cancer 1987; 39: 73-6.
143. Kavanaugh DY, Carbone DP. Immunologic dysfunction in cancer. Hematol Oncol Clin North Am 1996; 10: 927-951.
144. R Li, N Villacreses and S Ladisch. Human tumor gangliosides inhibit murine immune responses in vivo. Cancer Res 1995; 55: 211-214.
145. Ladisch S, Kitada S, Hays EF. Gangliosides shed by tumor cells enhance tumor formation in mice. J Clin Invest 1987; 79: 1879-82.
146. Esche C, Lokshin A, Shurin GV, et al. Tumor's other immune targets: dendrific cells. J Leukocyte Biol 1999; 66: 336-344.
147. Shurin GV, Shurin MR, Bykovskaia S, Shogan J, Lotze MT, Barksdale EM Jr. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res 2001; 61: 363-9.
148. Peguet-Navarro J, Sportouch M, Popa I, Berthier O, Schmitt D, Portoukalian J. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J Immunol 2003; 170: 3488-94.
149. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005; 41: 2502-12.
150. Atreya R, Neurath MF. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol 2005; 28: 187-96.
151. Blay JY, Rossi JF, Wijdenes J, et al. Role of interleukin-6 in the para-neoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 1997; 72: 424-30.
152. Sidell N, Taga T, Hirano T, Kishimoto T, Saxon A. Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. J Immunol 1991; 146: 3809-14.
153. Siegall CB, FitzGerald DJ, Pastan I. Cytotoxicity of IL6-PE40 and derivatives on tumor cells expressing a range of interleukin 6 receptor levels. J Biol Chem 1990; 265: 16318-23.
154. Barton BE. Interleukin-6 and new strategies for the treatment of cancer, hyper-proliferative diseases and para-neoplastic syndromes. Expert Opin Ther Targets 2005; 9: 737-52.
155. Bleier JI, Pillarisetty VG, Shah AB, DeMatteo RP. Increased and long-term generation of DC with reduced function from IL-6-deficient bone marrow. J Immunol 2004; 172: 7408-16.
156. Ratta M, Fagnoni F, Curti A, et al. DC are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002; 100: 230-7.
157. Menetrier-Caux C, Montmain G, Dieu MC, et al. Inhibition of the differentiation of DC from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998; 92: 4778-91.
158. Ratta M, Fagnoni F, Curti A, et al. DCare functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002; 100: 230-7.
159. Park SJ, Nakagawa T, Kitamura H, et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 2004; 173: 3844-54.
160. Gottfried E, Kunz-Schughart LA, Ebner S, et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood 2006; 107: 2013-21.
161. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999; 50: 507-29.
162. Gopal Murugaiyan, Saroj Basak, Bhaskar Saba. Dendritic cell-based immunotherapy: A promising approach for treatment of cancer. Gene Ther Mol Biol 2005; 9: 343-358.
163. Banchereau J, Palucka AK. DC as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5: 296-306.
164. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-74.